GLPwatch
Papers (12034)
Page 148 of 201, ranked by citation count.
- Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes.
- The Crunchometer, a low-cost, open-source acoustic analysis of feeding microstructure.
- Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation.
- Oral Semaglutide: Dosage in Special Situations.
- Semaglutide for the management of diabesity: The real-world experience.
- Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice.
- Perioperative bronchoaspiration in a semaglutide user on a residue-free diet: a case report and insights from a complication.
- Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder.
- Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.
- Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM: A Multicenter Real-World Study.
- Chemogenetic inhibition of the lateral hypothalamus effectively reduces food intake in rats in a translational proof-of-concept study.
- Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon- Like Peptide-1 Receptor Agonists - A Review.
- From the SELECT study to SOUL: different administration methods of semaglutide but same efficacy?
- Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus.
- Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy.
- Role of Gastric Point-of-Care Ultrasound in Perioperative Management of Semaglutide.
- The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.
- Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent.
- The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs.
- Therapy: Liraglutide - preventing or postponing T2DM diagnosis?
- Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
- Insulin secretion decline in Walker-256 tumor-bearing rats is early, follows the course of cachexia, and is not improved by lixisenatide.
- Lixisenatide in early parkinson's disease: efficacy, safety, and future directions: a correspondence.
- Localized Semaglutide Injection for Hyperinsulinemia-Induced Lymphatic Dysfunction: A Narrative Review Proposing a Promising Metabolic Perspective for Lymphedema Therapy.
- Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols.
- Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts.
- Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
- Semaglutide: UK regulator approves drug for prevention of cardiovascular events.
- Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
- IDegLira: combining efficacy, durability, and convenience?
- Analysis on difference in gastrointestinal hormone levels of patients with the history of diabetes and concurrent nephropathy and study on the role of liraglutide.
- Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.
- [Lixisenatide (Lyxumia), a new agonist of glucagon-like peptide-1 receptors with a predominant postprandial action].
- Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia.
- Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes.
- Comparison of PET/CT using <sup>68</sup>Ga-NOTA-Exendin-4 with <sup>68</sup>Ga-DOTATATE, <sup>18</sup>F-FDG, and conventional imaging in the localization of insulinomas.
- Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers.
- Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis.
- Editorial: Incretin agonists in the treatment of obesity.
- To Assess Liraglutide's Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System.
- Oral semaglutide (Rybelsus) for type 2 diabetes.
- [Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].
- Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog.
- Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.
- Tirzepatide for Heart Failure and Obesity.
- [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
- Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.
- Aliskiren, exendin-4, and insulin: their impact on endothelin receptor subtype(s) regulation/binding in type 1 diabetic rat hearts.
- Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
- Liraglutide Ameliorates Gamma Radiation-Induced Hepatic Damage in Rats: The Role of an Autophagy Flux Activation via LKB1/AMPK/mTOR Axis.
- Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease.
- Hedgehog interacting protein as a circulating biomarker in women with obesity: a cross-sectional study and intervention studies.
- Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- T2DM treatment trial results.
- Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population.
- Utilization patterns of glucagon like Peptide-1 receptor agonists prior to bariatric and metabolic surgery: a multicenter study.
- Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
- Effects of oral semaglutide on kidney outcomes in people with type 2 diabetes: a nationwide, multicentre, retrospective, observational study (Renal_ENDO2S-RWD substudy).
- Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting.
- A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules.